Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones

References

• WHO. Global Tuberculosis Report. 2016. Geneva: World Health Organization; 2016.
   Google Scholar
• Dheda K, Gumbo T, Gandhi NR, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014;2(4):321–338.
   PubMed Web of Science ®Google Scholar
• Lehner B. Molecular mechanisms of epistasis within and between genes. Trends Genet. 2011;27(8):323–331.
   PubMed Web of Science ®Google Scholar
• Breen MS, Kemena C, Vlasov PK, Notredame C, Kondrashov FA. Epistasis as the primary factor in molecular evolution. Nature. 2012;490(7421):535–538.
   PubMed Web of Science ®Google Scholar
• Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, Gordo I. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet. 2009;5(7):e1000578.
   PubMed Web of Science ®Google Scholar
• Müller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet. 2013;29(3):160–169.
   PubMed Web of Science ®Google Scholar
• Borrell S, Teo Y, Giardina F, et al. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med Public Health. 2013;2013(1):65–74.
   PubMedGoogle Scholar
• Committee TT. Streptomycin treatment of pulmonary tuberculosis: a medical research council investigation. Br Med J. 1948;2(4582):769–782.
   PubMedGoogle Scholar
• Pourakbari B, Mamishi S, Mohammadzadeh M, Mahmoudi S. First-line anti-tubercular drug resistance of Mycobacterium tuberculosis in Iran: a systematic review. Front Microbiol. 2016;7:1139.
   PubMedGoogle Scholar
• Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621–629.
   PubMed Web of Science ®Google Scholar
• Mir M, Prisic S, Kang CM, et al. Mycobacterial gene cuvA is required for optimal nutrient utilization and virulence. Infect Immun. 2014;82(10):4104–4117.
   PubMed Web of Science ®Google Scholar
• Singh AK, Carette X, Potluri LP, et al. Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system. Nucleic Acids Res. 2016;44(18):e143.
   PubMed Web of Science ®Google Scholar
• Guo JH, Xiang WL, Zhao QR, et al. Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Sichuan Province in China. Jpn J Infect Dis. 2008;61(4):264–268.
   PubMed Web of Science ®Google Scholar
• Zeng F, Chen Y, Remis J, et al. Structural basis of co-translational quality control by ArfA and RF2 bound to ribosome. Nature. 2017;541(7638):554–557.
   PubMed Web of Science ®Google Scholar
• Piton J, Petrella S, Delarue M, et al. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One. 2010;5(8):e12245.
   PubMed Web of Science ®Google Scholar
• Ford CB, Shah RR, Maeda MK, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013;45(7):784–790.
   PubMed Web of Science ®Google Scholar
• Jenkins C, Bacon J, Allnutt J, et al. Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH. J Antimicrob Chemother. 2009;63(6):1118–1120.
   PubMed Web of Science ®Google Scholar
• Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell. 2010;37(3):311–320.
   PubMed Web of Science ®Google Scholar
• Borrell S, Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect. 2011;17(6):815–820.
   PubMed Web of Science ®Google Scholar
• Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15(10):1193–1202.
   PubMed Web of Science ®Google Scholar
• Pelchovich G, Zhuravlev A, Gophna U. Effect of ribosome-targeting antibiotics on streptomycin-resistant Mycobacterium mutants in the rpsL gene. Int J Antimicrob Agents. 2013;42(2):129–132.
   PubMed Web of Science ®Google Scholar
• Javid B, Sorrentino F, Toosky M, et al. Mycobacterial mistranslation is necessary and sufficient for rifampicin phenotypic resistance. Proc Natl Acad Sci U S A. 2014;111(3):1132–1137.
   PubMed Web of Science ®Google Scholar
• Andersson DI. Persistence of antibiotic resistant bacteria. Curr Opin Microbiol. 2003;6(5):452–456.
   PubMed Web of Science ®Google Scholar
• Lee JH, Ammerman NC, Nolan S, et al. Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis. Nat Commun. 2012;3(2):753.
   PubMedGoogle Scholar
• Spies FS, von Groll A, Ribeiro AW, et al. Biological cost in Mycobacterium tuberculosis with mutations in the rpsL, rrs, rpoB, and katG genes. Tuberculosis. 2013;93(2):150–154.
   PubMed Web of Science ®Google Scholar
• Baker S, Duy PT, Nga TV, et al. Fitness benefits in fluoroquinolone-resistant Salmonella Typhi in the absence of antimicrobial pressure. Elife. 2013;2(49):e01229.
   PubMedGoogle Scholar
• Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Böttger EC. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol. 2010;77(4):830–840.
   PubMed Web of Science ®Google Scholar
• Vogwill T, Kojadinovic M, MacLean RC. Epistasis between antibiotic resistance mutations and genetic background shape the fitness effect of resistance across species of Pseudomonas. Proc Biol Sci. 2016;283(1830):20160151.
   PubMed Web of Science ®Google Scholar
• Durão P, Trindade S, Sousa A, Gordo I. Multiple resistance at no cost: rifampicin and streptomycin a dangerous liaison in the spread of antibiotic resistance. Mol Biol Evol. 2015;32(10):2675–2680.
   PubMed Web of Science ®Google Scholar
• Stower H. Molecular evolution: epistasis prevails. Nat Rev Genet. 2012;13(12):828.
   PubMed Web of Science ®Google Scholar
• Salvatore PP, Becerra MC, Abel zur Wiesch P, et al. Fitness costs of drug resistance mutations in multidrug-resistant Mycobacterium tuberculosis: a household-based case-control study. J Infect Dis. 2016;213(1):149–155.
   PubMed Web of Science ®Google Scholar